Property:Results after intervention
This is a property of type Text.
S
Shapiro et al. (2016): Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) +
NI +
Shapiro et al. (2016): Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) +
NI +
Shapiro et al. (2016): Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) +
NI +
Shapiro et al. (2016): Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) +
NI +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Sharp et al. (2010): A randomised, controlled trial of the psychological effects of reflexology in early breast cancer +
NA +
Shokri et al. (2017): Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients +
No significant difference between arms (p=0.55) +
Shokri et al. (2017): Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients +
Metastases on CT scan:
At T0 (Baseline), T2 (after 6 months) metastases significantly less frequent in intervention-arm than in placebo-arm
T0 (Baseline) intervention-arm vs. placebo-arm: 45% vs. 72.4% (p=0.05 )
T2 (after 6 months) intervention-arm vs. placebo-arm: 25% vs. 55.2% (p=0.04)
No significant difference between arms at the other time points.
Mortality: no significant difference between arms (p=0.68)
Unfavorable prognosis:
Unfavorable prognosis significantly less frequent in intervention-arm than in placebo-arm.
OR=3.3 p=0.04 +
Shokri et al. (2017): Comparison of the Complications of Platinum-Based Adjuvant Chemotherapy With and Without Ginger in a Pilot Study on Ovarian Cancer Patients +
Overall:
Nausea / vomiting: intervention-arm: 8, placebo-arm: 14 participants (p=0.57)
Weight loss: intervention-arm: 1, placebo-arm: 1 participant (p=0.66)
Peripheral neuropathy: intervention-arm: 3, placebo-arm: 5 participants (p=0.58)
Bone marrow depression: intervention-arm: 2, placebo-arm: 2 participants (p=0.54)
Temporary cortical blindness: intervention-arm: 1, placebo-arm: 0 participants (p=0.41)
Other side effects: intervention-arm: 10, placebo-arm: 21 participants (p= 0.11)
No significant differences between arms +
Shooriabi et al. (2016): The effect of ginger extract on radiotherapy-oriented salivation in patients with xerostomia: A double-blind controlled study +
Significantly higher increase in intervention-arm than in placebo-arm:
Mean (SD) intervention arm vs. placebo arm: 2.051 (0.659) vs. 0.997 (0.947); p<0.01 +
Shooriabi et al. (2016): The effect of ginger extract on radiotherapy-oriented salivation in patients with xerostomia: A double-blind controlled study +
Xerostomia symptoms:
Intervention-arm:
Significant improvement in: dry mouth, difficulty chewing / swallowing / speaking, burning sensation in mouth (general, daily, nightly), waking up at night, bad taste, saliva weight (p<0.05)
Placebo-arm:
Significant improvement in terms of:
dry mouth, difficulty chewing / swallowing, burning sensation in mouth (general, nightly), meeting people, saliva weight (p<0.05) +
Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study +
Complete control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 62% vs. 58% vs. 86%
placebo-ondansetron-arm significantly higher (p<0.01), no significant difference between ginger-arm and placebo-metoclopramide-arm
Partial control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 20% vs. 20% vs. 8%
No control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 18% vs. 22% vs. 6% +
Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study +
Reported side effects: oral ulcers (n=3), alopecia (n=5), diarrhea (n=2) +
Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study +
ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 80% vs. 82% vs. 95%
No significant difference
Low chemotherapy dose + highly emetogenic chemotherapy ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 14.3% vs. 15% vs. 29.5%
Placebo-ondansetron-arm significantly higher (p<0.01), no significant difference between ginger-arm and placebo-metoclopramide-arm
High chemotherapy dose ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 58.3% vs. 54.1% vs. 87.5%
Placebo-ondansetron-arm significantly higher (p<0.01), no significant difference between ginger-arm and placebo-metoclopramide-arm +
Sontakke et al. (2003): Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: A randomized, cross-over, double blind study +
Complete control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 68% vs. 64% vs. 86%
placebo-ondansetron-arm significantly higher (p<0.01), no significant difference between ginger-arm and placebo-metoclopramide-arm
Partial control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 26% vs. 34% vs. 14%
No control ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 6% vs. 2% vs. 0%
Frequency 0-12h after chemotherapy ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 10 vs. 9 vs. 3
12-24h after chemotherapy ginger-arm vs. placebo-metoclopramide-arm vs. placebo-ondansetron-arm: 20 vs. 19 vs. 6
In all three arms, the frequency of vomiting was significantly higher after 12-24h than after 0-12h (p<0.05) +